Recent Updates
Recently added Catalysts
RANI Positive Sentiment

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rani Therapeutics Holdings, Inc. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. This event highlights the company's focus on oral delivery of biologics and provides an opportunity for management to engage with investors and stakeholders. The participation reflects Rani's commitment to advancing its clinical-stage biotherapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rani Therapeutics is actively participating in a prominent conference.
  • The event showcases the company's commitment to growth and visibility.
  • Management's involvement indicates confidence in their oral delivery technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~21 mo
Low dilution risk
Lead asset
Stelara
Phase 1 · Healthy Volunteers

Full Press Release Details

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming Canaccord Genuity 46th Annual

Frequently Asked Questions

What conference will Rani Therapeutics attend?

Rani Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference.

What is the focus of Rani Therapeutics?

Rani Therapeutics focuses on the oral delivery of biologics.

When was the announcement made?

The announcement was made on August 10, 2026.

What is the significance of this conference for Rani?

The conference provides a platform for Rani to engage with investors and showcase its technology.

ShareAdd on Google
Tags: RANI Viatris Investor Conferences Healthcare Rani Therapeutics Canaccord Genuity biotherapeutics oral delivery clinical-stage
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$52M liquidity · $2M/mo burn
~21 mo
Low dilution risk
Lead asset
StelaraPhase 1
Healthy Volunteers →